NCT02611037 2025-12-18
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
Clinical Trials
9 trialsNCT03560973 2025-03-13
RAMES
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Completed
NCT05660616 2024-08-27
Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma
Ain Shams University
Phase 2 Completed
NCT00101283 2023-07-03
Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00859469 2019-10-30
Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma
Columbia University
Phase 2 Completed
NCT00571298 2017-01-23
Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01281800 2011-01-24
AGILI
Institute of Oncology Ljubljana
Phase 2 Unknown
NCT00551252 2007-10-30
A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma
Gruppo Italiano MEsotelioma
Phase 2 Unknown
NCT00061477 2007-01-26
Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma
Eli Lilly and Company
Phase 2 Completed